Vitamin D deficiency, which is a recognized problem in haemodialysis (HD) patients, has been associated with higher all-cause mortality. There are no guidelines concerning vitamin D supplementation in HD patients. This study aimed to assess the effects of once-monthly supplementation with high-dose cholecalciferol (vitamin D3) in HD patients. Patients with 25-hydroxyvitamin D (25[OH]D) levels of < 75 nmol/l received 40 000 IU of cholecalciferol once-monthly for 3 months in succession. Every 4 months, 25(OH)D levels were measured and, based on the findings, cholecalciferol therapy was continued for another cycle if necessary. Six cycles were completed in the 24-month study period. The majority of HD patients had mild or severe vitamin D deficiency at baseline. Monthly supplementation with cholecalciferol at 40000 IU was well tolerated, safe and inexpensive. The treatment regime was effective for vitamin D insufficiency but did not prove to be enough to restore 25(OH)D levels in HD patients with mild or severe vitamin D deficiency.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD—MBD Work Group: KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD—MBD). Kidney Int Suppl2009; 113: S1–S130.
2.
LondonGMGuérinAPVerbekeFH: Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol2007; 18: 613–620.
3.
Pecovnik-BalonBJakopinEBevcS: Vitamin D as a novel nontraditional risk factor for mortality in hemodialysis patients. Ther Apher Dial2009; 13: 268–272.
4.
WolfMShahAGutierrezO: Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int2007; 72: 1004–1013.
5.
JonesG: Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1α-hydroxylase in the classical and nonclassical actions of 1α,25-dihydroxyvitamin D3. Semin Dial2007; 20: 316–324.
6.
HolickMF: Sunlight and vitamin D for bone health and prevention of autoimmune disease, cancers, and cardiovascular disease. Am J Clin Nutr2004; 80 (6 suppl): 1678S–1688S.
7.
National Kidney Foundation: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis2003; 42 (4 suppl 3): S1–S201.
8.
HsiaJHeissGRenH: Calcium/vitamin D supplementation and cardiovascular events. Circulation2007; 115: 846–854.
9.
SaabGYoungDOGinchermanY: Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract2007; 105: c132–c138.
10.
TokmakFQuackISchierenG: High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant2008; 23: 4016–4020.
11.
JeanGSouberbielleJCChazotC: Monthly cholecalciferol administration in haemodialysis patients: A simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant2009; 24: 3799–3805.
12.
JeanGTerratJCVanelT: Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant2008; 23: 3670–3676.
13.
Al-AlyZQaziRAGonzálezEA: Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis2007; 50: 59–68.
14.
MaheutHChevriotFMartyH: Why and how correct calcidiol deficiency in haemodialysis patients?Nephrol Ther2009; 5: 542–549 [in French, English abstract].
15.
JeanGChazotC: The French clinician's guide to the kidney disease: improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD). Nephrol Ther2010; 6: 151–157 [in French, English abstract].
16.
TaskapanHWeiMOreopoulosDG: 25(OH) Vitamin D3 in patients with chronic kidney disease and those on dialysis: rediscovering its importance. Int Urol Nephrol2006; 38: 323–329.
17.
GonzálesEASachdevaAOliverDA: Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol2004; 24: 503–510.
18.
CigoliniMIagulliMPMiconiV: Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. Diabetes Care2006; 29: 722–724.
19.
ZittermanASchleithoffSSTenderichG: Low vitamin D status: A contributing factor in the pathogenesis of congestive heart failure?J Am Coll Cardiol2003; 41: 105–112.
20.
ScraggRJacksonRHoldawayIM: Myocardial infarction is inversly associated with plasma 25-hydroxyvitamin D3 levels: A community-based study. Int J Epidemiol1990; 19: 559–563.
21.
WangTJPencinaMJBoothSL: Vitamin D deficiency and risk of cardiovascular disease. Circulation2008; 117: 503–511.
22.
ArmasLAHollisBWHeaneyRP: Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab2004; 89: 5387–5391.
23.
TrangHColeDERuinLA: Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr1998; 68: 854–858.
24.
NilssonSFOstbergLPetersonPA: Binding of vitamin D to its human carrier plasma protein. Biochem Biophys Res Commun1972; 46: 1380–1387.
25.
MistrettaVIDelanayePChapelleJP: Vitamin D2 or vitamin D3?Rev Med Interne2008; 29: 815–820 [in French, English abstract].
